相似文献
1
A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.
J Infect Dis. 2009 Mar 1;199(5):711-6. doi: 10.1086/596558.
2
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
Vaccine. 2009 Jun 8;27(28):3744-53. doi: 10.1016/j.vaccine.2009.03.082. Epub 2009 Apr 17.
3
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Lancet Infect Dis. 2017 Aug;17(8):833-842. doi: 10.1016/S1473-3099(17)30240-2. Epub 2017 May 19.
4
An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.
Influenza Other Respir Viruses. 2013 Jan;7(1):66-73. doi: 10.1111/j.1750-2659.2012.00350.x. Epub 2012 Mar 14.
5
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.
Vaccine. 2009 Aug 6;27(36):4953-60. doi: 10.1016/j.vaccine.2009.05.099. Epub 2009 Jun 21.
6
Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Clin Vaccine Immunol. 2015 Jan;22(1):46-55. doi: 10.1128/CVI.00275-14. Epub 2014 Oct 29.
7
Cross- immunity of a H9N2 live attenuated influenza vaccine against H5N2 highly pathogenic avian influenza virus in chickens.
Vet Microbiol. 2018 Jul;220:57-66. doi: 10.1016/j.vetmic.2018.05.005. Epub 2018 May 21.
8
An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults.
Vaccine. 2011 Apr 12;29(17):3144-8. doi: 10.1016/j.vaccine.2011.02.043. Epub 2011 Mar 4.
9
Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
J Virol. 2017 Feb 28;91(6). doi: 10.1128/JVI.01693-16. Print 2017 Mar 15.
10
Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Vaccine. 2015 Sep 22;33(39):5110-7. doi: 10.1016/j.vaccine.2015.08.019. Epub 2015 Aug 19.
引用本文的文献
1
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.
ACS Nano. 2024 Sep 10;18(36):24650-24681. doi: 10.1021/acsnano.3c10797. Epub 2024 Aug 26.
2
Pandemic preparedness through vaccine development for avian influenza viruses.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2347019. doi: 10.1080/21645515.2024.2347019. Epub 2024 May 28.
3
Univ-flu: A structure-based model of influenza A virus hemagglutinin for universal antigenic prediction.
Comput Struct Biotechnol J. 2022 Aug 28;20:4656-4666. doi: 10.1016/j.csbj.2022.08.052. eCollection 2022.
4
Live Attenuated Cold-Adapted Influenza Vaccines.
Cold Spring Harb Perspect Med. 2021 Sep 1;11(9):a038653. doi: 10.1101/cshperspect.a038653.
5
Immunogenicity and Protective Efficacy of Seasonal Human Live Attenuated Cold-Adapted Influenza Virus Vaccine in Pigs.
Front Immunol. 2019 Nov 8;10:2625. doi: 10.3389/fimmu.2019.02625. eCollection 2019.
6
Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines.
JCI Insight. 2019 Nov 14;4(22):129035. doi: 10.1172/jci.insight.129035.
7
How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
J Infect Dis. 2019 Apr 8;219(Suppl_1):S81-S87. doi: 10.1093/infdis/jiy703.
8
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01970-17. Print 2018 May 1.
9
Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).
J Infect Dis. 2016 Mar 15;213(6):922-9. doi: 10.1093/infdis/jiv526. Epub 2015 Dec 9.
10
Refining the approach to vaccines against influenza A viruses with pandemic potential.
Future Virol. 2015;10(9):1033-1047. doi: 10.2217/fvl.15.69.
本文引用的文献
1
Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model.
J Virol. 2007 Oct;81(19):10558-66. doi: 10.1128/JVI.00970-07. Epub 2007 Jul 18.
2
A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.
Vaccine. 2007 Jul 20;25(29):5367-73. doi: 10.1016/j.vaccine.2007.05.002. Epub 2007 May 22.
3
Three Indonesian clusters of H5N1 virus infection in 2005.
N Engl J Med. 2006 Nov 23;355(21):2186-94. doi: 10.1056/NEJMoa060930.
4
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
Clin Infect Dis. 2006 Nov 1;43(9):1135-42. doi: 10.1086/508174. Epub 2006 Sep 25.
5
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
PLoS Med. 2006 Sep;3(9):e360. doi: 10.1371/journal.pmed.0030360.
6
Development of effective vaccines against pandemic influenza.
Immunity. 2006 Jan;24(1):5-9. doi: 10.1016/j.immuni.2005.12.005.
7
Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.
Lancet. 2003 Dec 13;362(9400):1959-66. doi: 10.1016/S0140-6736(03)15014-3.
8
Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate.
Vaccine. 2003 Oct 1;21(27-30):4430-6. doi: 10.1016/s0264-410x(03)00430-4.
9
Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
Med Microbiol Immunol. 2002 Dec;191(3-4):203-8. doi: 10.1007/s00430-002-0147-9. Epub 2002 Oct 19.
10
Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.
Viral Immunol. 2002;15(2):295-323. doi: 10.1089/08828240260066242.
Zotero 插件